DETERMINATION OF PROPHYLACTIC EFFICACY OF VARIOUS HEPATITS C VIRUS VACCINES

各种丙型肝炎病毒疫苗预防效果的测定

• 批准号: 7349763
• 负责人: KATHLEEN M BRASKY
• 金额: $ 1.19万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349763
• 关键词: DETERMINATION; PROPHYLACTIC; EFFICACY; VARIOUS; HEPATITS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is an urgent medical need for a preventive HCV vaccine. HCV infection occurs commonly around the globe as a result of parenteral exposure to the virus. In developed countries, the most common risk factor is sharing of needles amongst iv drug users. Other ¿at-risk¿ groups include babies born to positive mothers, individuals with frequent and multiple heterosexual partners, health-care workers, individuals with an infected family member, and hemodialysis patients. In the USA, the CDC has estimated that there are roughly 30,000 new infections annually. In developing countries, the same risk factors are evident but in addition, non-sterile medical injection practices have contributed hugely and tragically to the current disease burden. Cultural practices involving parenteral exposure to the virus are also thought to play an important role in transmission in the developing world. Therefore, there is an urgent need for the development of a prophylactic vaccine. We intend to test efficacy against a delayed challenge with a heterologous HCV strain. Several candidate vaccines will be tested in groups of 5 chimpanzees for the elicitation of humoral and cellular immune responses to HCV. The demonstration of significant immunogenicity will then lead to challenge of vaccines with a heterologous 1a HCV strain. This study is in progress. Results will be proprietary. Future directions will be determined by the commercial spo

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。目前迫切需要预防性丙型肝炎疫苗。由于肠外接触病毒，HCV 感染在全球范围内普遍发生。在发达国家，最常见的风险因素是静脉注射吸毒者共用针头。其他“高危”群体包括阳性母亲所生的婴儿、经常有多个异性伴侣的人、卫生保健工作者、有受感染家庭成员的人以及血液透析患者。在美国，疾病预防控制中心估计每年大约有 30,000 例新感染病例。在发展中国家，同样的风险因素也很明显，但除此之外，非无菌医疗注射做法对当前的疾病负担造成了巨大而悲惨的影响。涉及肠外接触病毒的文化习俗也被认为在发展中国家的传播中发挥着重要作用。因此，迫切需要开发预防性疫苗。我们打算测试异源 HCV 毒株对延迟攻击的功效。几种候选疫苗将以 5 只黑猩猩为一组进行测试，以激发针对 HCV 的体液和细胞免疫反应。显着免疫原性的证明将导致对异源 1a HCV 毒株的疫苗进行挑战。这项研究正在进行中。结果将是专有的。未来的方向将由商业空间决定